60 Degrees Pharma Signs Clinical Trial Agreement With Icahn School Of Medicine At Mount Sinai In New York City As Central Site For Phase II Clinical Study Of Tafenoquine In Treating Chronic Babesiosis

• 90-day trial measuring change in general fatigue in chronic babesiosis patients
• Enrollment expected to commence Q4 2025 and to be completed by Q2 2026
• Site has clinical expertise in infectious disease trials and access to a robust patient population with tick-borne illness, including chronic babesiosis
• No FDA-approved treatment exists for chronic babesiosis, a debilitating illness

WASHINGTON, Aug. 19, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP, SXTPW))) ("60 Degrees Pharma" or the "Company"), a pharmaceutical company focused on developing new medicines for vector-borne disease, announced today it has signed a clinical trial agreement with the Icahn School of Medicine at Mount Sinai in New York City as the central site for a Phase II clinical study of tafenoquine in treating chronic babesiosis.